CA2996059A1 - Anti-siglec-7 antibodies and methods of use thereof - Google Patents

Anti-siglec-7 antibodies and methods of use thereof Download PDF

Info

Publication number
CA2996059A1
CA2996059A1 CA2996059A CA2996059A CA2996059A1 CA 2996059 A1 CA2996059 A1 CA 2996059A1 CA 2996059 A CA2996059 A CA 2996059A CA 2996059 A CA2996059 A CA 2996059A CA 2996059 A1 CA2996059 A1 CA 2996059A1
Authority
CA
Canada
Prior art keywords
amino acid
siglec
seq
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2996059A
Other languages
English (en)
French (fr)
Inventor
Kate MONROE
Helen LAM
Arnon Rosenthal
Seung-Joo Lee
Francesca Avogadri-Connors
William Monteith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alector LLC
Original Assignee
Alector LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector LLC filed Critical Alector LLC
Publication of CA2996059A1 publication Critical patent/CA2996059A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2996059A 2015-08-28 2016-08-26 Anti-siglec-7 antibodies and methods of use thereof Abandoned CA2996059A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211656P 2015-08-28 2015-08-28
US62/211,656 2015-08-28
US201562265742P 2015-12-10 2015-12-10
US62/265,742 2015-12-10
PCT/US2016/049032 WO2017040301A1 (en) 2015-08-28 2016-08-26 Anti-siglec-7 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2996059A1 true CA2996059A1 (en) 2017-03-09

Family

ID=56853902

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2996059A Abandoned CA2996059A1 (en) 2015-08-28 2016-08-26 Anti-siglec-7 antibodies and methods of use thereof

Country Status (9)

Country Link
US (3) US10590198B2 (https=)
EP (1) EP3341411B1 (https=)
JP (3) JP7525980B2 (https=)
KR (1) KR20180054639A (https=)
CN (2) CN115960235A (https=)
AU (1) AU2016316768A1 (https=)
CA (1) CA2996059A1 (https=)
HK (1) HK1252696A1 (https=)
WO (1) WO2017040301A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017123745A1 (en) * 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
JP7137563B2 (ja) * 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体
CN116492457A (zh) * 2016-09-10 2023-07-28 耶达研究与开发有限公司 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤
US11578137B2 (en) * 2017-03-06 2023-02-14 The Trustees Of The University Of Pennsylvania Anti-C5 antibodies and uses thereof
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018200473A1 (en) * 2017-04-24 2018-11-01 The General Hospital Corporation Detection and targeting of tumor-promoting neutrophils cross-reference to related applications
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019140273A1 (en) * 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
US20210395333A1 (en) * 2018-06-07 2021-12-23 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
CN112384532B (zh) * 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
CA3111396A1 (en) 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
MX2022001260A (es) * 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
KR20220166837A (ko) * 2020-06-11 2022-12-19 난징 바이오흐엥 바이오테크 씨오., 엘티디 Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도
CN111647084B (zh) * 2020-06-13 2020-12-01 广东赛尔生物科技有限公司 抗c-MET抗体及其在治疗癌症中的应用
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
JP2025500457A (ja) * 2021-12-23 2025-01-09 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体
WO2023192993A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy
CN118146371A (zh) * 2024-03-07 2024-06-07 中国科学技术大学 靶向Siglec-7蛋白的纳米抗体及其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140542A1 (en) 1992-07-27 1994-02-03 Abeysingle Padmapriya Oligonucleotide alkylphosphonothioates
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
AU684748B2 (en) 1993-01-21 1998-01-08 Hybridon, Inc. Foldback triplex-forming oligonucleotides
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5955599A (en) 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US5614622A (en) 1995-06-01 1997-03-25 Hybridon, Inc. 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
US6140482A (en) 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
AU4089397A (en) 1996-08-26 1998-03-19 Hybridon, Inc. Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP4768132B2 (ja) 1999-03-24 2011-09-07 エクシコン エ／エス ［２．２．１］ビシクロヌクレオシドの改良された製法
KR20010001577A (ko) 1999-06-07 2001-01-05 윤종용 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법
AU6629200A (en) 1999-08-25 2001-03-19 Philip P Garner Alpha-helical peptide nucleic acid alpha-pna
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
IT1307826B1 (it) * 1999-12-16 2001-11-19 Dipartimento Di Medicina Speri Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
AU2001274939A1 (en) * 2000-05-24 2001-12-03 Smith Kline Beecham Corporation Sialoadhesin factor-3 antibodies
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2628753A1 (en) * 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9175092B2 (en) * 2011-06-28 2015-11-03 Oxford Biotherapeutics Ltd Antibodies to bone marrow stromal antigen 1
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
US10047167B2 (en) * 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TW201734054A (zh) * 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
PE20160993A1 (es) * 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
JP2017532025A (ja) * 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
US10227408B2 (en) * 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
MX2018016393A (es) 2016-07-01 2019-08-12 Univ Leland Stanford Junior Conjugados para la edición de la superficie de la celula diana.
CN106831989A (zh) 2017-01-04 2017-06-13 中国人民解放军南京军区军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
WO2019140273A1 (en) 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.

Also Published As

Publication number Publication date
EP3341411B1 (en) 2025-06-11
HK1252696A1 (zh) 2019-05-31
CN108137702A (zh) 2018-06-08
AU2016316768A1 (en) 2018-03-29
US10590198B2 (en) 2020-03-17
US20180244770A1 (en) 2018-08-30
JP2024009818A (ja) 2024-01-23
WO2017040301A1 (en) 2017-03-09
CN108137702B (zh) 2023-01-06
JP2022028653A (ja) 2022-02-16
KR20180054639A (ko) 2018-05-24
US11390680B2 (en) 2022-07-19
JP7525980B2 (ja) 2024-07-31
JP2018525999A (ja) 2018-09-13
US20220411503A1 (en) 2022-12-29
US20200277374A1 (en) 2020-09-03
EP3341411A1 (en) 2018-07-04
CN115960235A (zh) 2023-04-14

Similar Documents

Publication Publication Date Title
US20240067723A1 (en) Anti-siglec-9 antibodies and methods of use thereof
US20220411503A1 (en) Anti-siglec-7 antibodies and methods of use thereof
US20220162309A1 (en) Anti-cd33 antibodies and methods of use thereof
CA2988982A1 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201389A2 (en) Anti-cd33 antibodies and methods of use thereof
US12258398B2 (en) Anti-Siglec-5 antibodies and methods of use thereof
US20250145709A1 (en) Anti-siglec-7 antibodies and methods of use thereof
IL293772A (en) Methods of use of anti-cd33 antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210817

FZDE Discontinued

Effective date: 20240304